Lung Cancer Edition: Top Headlines for Week of April 18, 2022

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

Read the full coverage here:

Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint

Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery

Lung cancer screening less common among those most likely to benefit from it

FDA rejects sintilimab with chemotherapy for non-small cell lung cancer

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

References:

Press Release

Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC.

Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318.

Press Release

Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y.